Share
15,564 Posts.
lightbulb Created with Sketch. 5622
clock Created with Sketch. 19/04/22
12:30
Share
Originally posted by chrisnj
↑
The share price is not the issue here, it's performance of management that's the issue which in turn reflects on the SP
Expand
Gilead didn't seem to be interested in DEP® Remdesivir or certainly didn't proceed in the last 2 years if they were since JF spruiked about it, so I wonder with this new announcement today if any other DEP® products for oncology will interest them ? https://www.fiercepharma.com/pharma...-seeing-33-revenue-coming-oncology-drugs-2030 Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030 Kevin Dunleavy Apr 19, 2022 05:15am
